Aclaris Therapeutics, Inc. (ACRS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.13B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-304.00K; Retained Earnings (Accumulated Deficit)USD $-1.01B.
- 2026-03-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.13B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $22.00K; Retained Earnings (Accumulated Deficit)USD $-987.61M.
- 2025-12-31: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.07B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $610.00K; Retained Earnings (Accumulated Deficit)USD $-967.78M.
- 2025-09-30: Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $1.07B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $597.00K; Retained Earnings (Accumulated Deficit)USD $-947.99M.
Aclaris Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.00K | $1.13B | $-304.00K | $-1.01B | $124.58M | (m) | 3 month · $2.67M | (m) | (m) |
| 2026-03-31 | $1.00K | $1.13B | $22.00K | $-987.61M | $143.65M | (m) | 3 month · $3.20M | (m) | (m) |
| 2025-12-31 | $1.00K | $1.07B | $610.00K | $-967.78M | $103.08M | (m) | 12 month · $12.38M | (m) | (m) |
| 2025-09-30 | $1.00K | $1.07B | $597.00K | $-947.99M | $120.10M | (m) | 3 month · $2.86M | (m) | (m) |
| 2025-06-30 | $1.00K | $1.06B | $482.00K | $-933.38M | $131.74M | (m) | 3 month · $3.06M | (m) | (m) |
| 2025-03-31 | $1.00K | $1.06B | $434.00K | $-917.95M | $144.07M | (m) | 3 month · $3.54M | (m) | (m) |
| 2024-12-31 | $1.00K | $1.06B | $97.00K | $-902.86M | $155.55M | 12 month · $5.09M | 12 month · $10.86M | 12 month · $44.84M | (m) |
| 2024-09-30 | $1.00K | $936.03M | $427.00K | $-806.31M | $130.15M | (m) | 3 month · $3.00M | (m) | (m) |
| 2024-06-30 | $1.00K | $933.01M | $-463.00K | $-798.72M | $133.82M | (m) | 3 month · $2.90M | (m) | (m) |
| 2024-03-31 | $1.00K | $930.11M | $-364.00K | $-787.74M | $142.01M | (m) | 3 month · $2.09M | (m) | (m) |
| 2023-12-31 | $1.00K | $928.08M | $-106.00K | $-770.80M | $157.18M | 12 month · $826.00K | 12 month · $20.54M | (m) | (m) |
| 2023-09-30 | $1.00K | $926.77M | $-1.13M | $-769.30M | $156.33M | (m) | 3 month · $5.95M | (m) | (m) |
| 2023-06-30 | $1.00K | $920.90M | $-1.11M | $-740.04M | $179.75M | 3 month · $826.00K | 3 month · $6.52M | (m) | (m) |
| 2023-03-31 | $1.00K | $887.64M | $-354.00K | $-710.48M | $176.81M | (m) | 3 month · $6.81M | (m) | (m) |
| 2022-12-31 | $1.00K | $880.83M | $-897.00K | $-682.32M | $197.62M | (m) | 12 month · $15.04M | (m) | (m) |
| 2022-09-30 | $1.00K | $875.98M | $-1.47M | $-654.68M | $219.84M | (m) | 3 month · $4.19M | (m) | (m) |
| 2022-06-30 | $1.00K | $871.80M | $-1.33M | $-634.73M | $235.75M | (m) | 3 month · $3.69M | (m) | (m) |
| 2022-03-31 | $1.00K | $795.37M | $-972.00K | $-614.20M | $180.20M | (m) | 3 month · $2.35M | (m) | (m) |
| 2021-12-31 | $1.00K | $792.97M | $-224.00K | $-595.41M | $197.34M | (m) | 12 month · $14.06M | (m) | (m) |
| 2021-09-30 | $1.00K | $789.19M | $-3.00K | $-572.60M | $216.58M | (m) | 3 month · $3.70M | (m) | (m) |
| 2021-06-30 | $1.00K | $785.46M | $-184.00K | $-551.46M | $233.81M | (m) | 3 month · $3.83M | (m) | (m) |
| 2021-03-31 | (m) | $645.73M | $-140.00K | $-533.30M | $112.29M | (m) | 3 month · $2.67M | (m) | (m) |
| 2020-12-31 | (m) | $542.29M | $-94.00K | $-504.54M | $37.65M | (m) | 12 month · $11.21M | 12 month · $378.00K | (m) |
| 2020-09-30 | (m) | $532.17M | $-44.00K | $-491.37M | $40.76M | (m) | 3 month · $1.94M | (m) | (m) |
| 2020-06-30 | (m) | $530.06M | $15.00K | $-480.71M | $49.37M | (m) | 3 month · $3.31M | (m) | (m) |
| 2020-03-31 | (m) | $527.24M | $47.00K | $-469.11M | $58.15M | (m) | 3 month · $3.45M | 3 month · $378.00K | (m) |
| 2019-12-31 | (m) | $523.50M | $-66.00K | $-453.53M | $69.91M | (m) | 12 month · $16.18M | (m) | (m) |
| 2019-09-30 | (m) | $520.21M | $-1.00K | $-434.93M | $85.28M | (m) | 3 month · $3.32M | (m) | (m) |
| 2019-06-30 | (m) | $516.84M | $8.00K | $-379.61M | $137.23M | (m) | 3 month · $4.81M | (m) | (m) |
| 2019-03-31 | (m) | $512.04M | $-49.00K | $-329.74M | $182.25M | (m) | 3 month · $4.86M | (m) | (m) |
| 2018-12-31 | (m) | $507.37M | $-69.00K | $-292.17M | $215.12M | (m) | 12 month · $20.05M | (m) | (m) |
| 2018-09-30 | (m) | $400.07M | $-116.00K | $-253.62M | $146.33M | (m) | 3 month · $4.71M 9 month · $15.10M | (m) | (m) |
| 2018-06-30 | (m) | $395.27M | $-188.00K | $-220.88M | $174.20M | (m) | 3 month · $5.25M 6 month · $10.39M | (m) | (m) |
| 2018-03-31 | (m) | $390.46M | $-328.00K | $-189.66M | $200.47M | (m) | 3 month · $5.14M | (m) | (m) |
| 2017-12-31 | (m) | $384.94M | $-246.00K | $-159.44M | $225.26M | 12 month · $5.35M | 12 month · $14.43M | (m) | (m) |
| 2017-09-30 | (m) | $380.87M | $-113.00K | $-136.50M | $244.26M | (m) | 9 month · $10.13M | (m) | (m) |
| 2017-06-30 | (m) | $286.62M | $-166.00K | $-118.31M | $168.14M | (m) | 6 month · $6.46M | (m) | (m) |
| 2017-03-31 | (m) | $264.01M | $-249.00K | $-103.47M | $160.29M | (m) | 3 month · $3.15M | (m) | (m) |
| 2016-12-31 | (m) | $260.67M | $-269.00K | $-90.91M | $169.49M | (m) | 12 month · $6.10M | (m) | (m) |
| 2016-09-30 | (m) | $160.61M | $-54.00K | $-79.44M | $81.12M | 9 month · $1.45M | 9 month · $4.19M | (m) | (m) |
| 2016-06-30 | (m) | $158.98M | $1.00K | $-68.74M | $90.24M | 6 month · $1.45M | 6 month · $2.58M | (m) | (m) |
| 2016-03-31 | (m) | $139.08M | $3.00K | $-55.87M | $83.21M | (m) | 3 month · $1.22M | (m) | (m) |
| 2015-12-31 | (m) | $135.50M | $-149.00K | $-42.83M | $92.52M | 12 month · $0.00 | 12 month · $891.00K | (m) | (m) |
| 2015-09-30 | (m) | (m) | $1.00K | $-38.12M | $-38.12M | (m) | 9 month · $243.00K | (m) | 9 month · $1.76M |
| 2014-12-31 | (m) | (m) | $-6.00K | $-20.75M | $-20.75M | 12 month · $0.00 | 12 month · $27.00K | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-9.16M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $-2.19M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |